Table 2.
Institutional regulatory capability.
| Location Institution* |
BSL-3 | BSL-3+ | BSL-4 | Select Agent |
Tier I | GLP≠ | GMP≠ |
|---|---|---|---|---|---|---|---|
| Duke U Human Vaccine Institute Regional Biocontainment Laboratory (RBL) | Y | Y | N | Y | Y | Y | N |
| Colorado State University RBL | Y | Y | N | Y | Y | Limited | Y |
| University of Pittsburgh, Center for Vaccine Research RBL | Y | Y | N | Y | Y | N | N |
| University of Alabama Birmingham Southeast Biosafety Laboratory Alabama (SEBLAB) | Y | N | N | Y | Y | N | N |
| University of Chicago The Howard T. Ricketts Laboratory (HTRL) | Y | Y | N | Y | Y | N | N |
| University of Medicine and Dentistry of New Jersey RBL | Y | N | N | Y | Y | Y | N |
| University of Missouri-Columbia RBL | Y | N | N | Y | Y | N | N |
| Tufts University/New England RBL (NE-RBL) | Y | N | N | Y | ? | N | N |
| Tulane National Primate Research Center RBL | Y | Y | N | Y | Y | N | N |
| University of Tennessee Health Science Center RBL | Y | N | N | Y | Y | Y | N |
| University of Louisville Center for Predictive Medicine RBL | Y | Y | N | Y | Y | Y | Limited |
| George Mason University/Biomedical Research Laboratory (BRL) | Y | N | N | Y | Y | Y | N |
| University of Texas Medical Branch at Galveston/National Laboratory (GNL) | Y | Y | Y | Y | Y | Y | N |
| Boston University# National Emerging Infectious Diseases Laboratory (NEIDL)# | Y | Y | Y | Y | Y | N | N |
*
At the writing of this review The University of Hawaii RBL had not yet begun construction.
#
The Boston University NEIDL had been completed and occupied at BSL2; date for occupancy at BSL3/4 was pending.
≠
GLP-good laboratory practice, good manufacturing practice